Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis

INTRODUCTION: Peficitinib, a Janus kinase (JAK) inhibitor, is approved for clinical use in Japan, Korea, and Taiwan, but head-to-head comparisons versus other JAK inhibitors are lacking. We indirectly compared peficitinib, tofacitinib, and baricitinib for rheumatoid arthritis treatment. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Okumura, Hiroyuki, Kim, Soyoung, Dorey, Julie, Wojciechowski, Piotr, Chorąży, Justyna, Kato, Daisuke, Schultz, Neil M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217393/
https://www.ncbi.nlm.nih.gov/pubmed/33725321
http://dx.doi.org/10.1007/s40744-021-00284-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217393/
https://www.ncbi.nlm.nih.gov/pubmed/33725321
http://dx.doi.org/10.1007/s40744-021-00284-1

Ejemplares similares